This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Zenaide M. N. Quezado, MD; Charles Natanson, MD; William D. Hoffman, MD

Arch Intern Med. 1994;154(21):2393.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THIS ISSUE of the ARCHIVES, The National Committee for the Evaluation of Centoxin1 reports data from a French national registry that monitored the outcome of 600 septic patients given a single 100-mg dose of HA-1A (Centoxin, Centocor, Malvern, Pa), a sepsis drug that was recently approved for, and then withdrawn from, clinical use in Europe. The authors show that patients treated with HA-1A had a higher mortality rate than would have been expected from their scores measured by means of the Acute Physiology and Chronic Health Evaluation II (APACHE II). The study was retrospective and compared HA-1A—associated mortality with APACHE II—predicted mortality, rather than a simultaneously treated control group. Although the P value of.06 for increased mortality did not reach statistical significance, P values less than.¹ are more than adequate to suggest evidence of harm. Despite these potential limitations, the French findings should prompt a reexamination of the sequence . . . [Full Text PDF of this Article]

Author Affiliations
Critical Care Medicine Department National Institutes of Health Bethesda, MD 20892

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?